A Phase I-II Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia

What is the purpose of this trial?

The purpose of this study is to determine if a combination of nintedanib+ induction chemotherapy can be an effective strategy for patients where outcome of relapse/refractory acute myeloid leukemia (AML) is poor.

Yale Cancer Center

Start Date: 06/15/2016

End Date: 07/01/2018

Last Updated: 06/22/2018

Study HIC#: 1507016193